Valuation: Cogent Biosciences, Inc.

Market Cap 5.8B 5.02B 4.74B 4.3B 8.07B 556B 8.13B 56.63B 21.82B 282B 21.78B 21.3B 896B P/E 2026 *
-14.8x
P/E 2027 * -31.8x
Enterprise Value 5.67B 4.91B 4.64B 4.21B 7.89B 543B 7.95B 55.37B 21.33B 276B 21.29B 20.82B 876B EV / Sales 2026 *
947x
EV / Sales 2027 * 19.1x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 week-3.88%
Current month-4.54%
1 month-11.92%
3 months+0.94%
6 months-1.74%
Current year-5.94%
1 week 32.85
Extreme 32.85
35.57
1 month 32.85
Extreme 32.85
38.62
Current year 30.87
Extreme 30.87
43.39
1 year 11.6
Extreme 11.6
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/27/26 A Exercice

Director

136,530 0.0787%
7/1/26 A Free

Director

627 0.0004%
6/9/26 A Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.88%+163.90%+185.07% 5.8B
+5.04%+3.66%+50.62%+103.77% 66.93B
+1.64%-0.18%+34.67%+76.81% 61.97B
-3.18%-0.78%-14.14%+369.82% 28.26B
+0.16%-0.16%+26.73%+12.12% 24.59B
+2.20%-4.72%+2.19%-13.14% 24.3B
+1.15%-1.17%+17.56%-21.92% 19.41B
-7.03%-10.19%+161.91%+303.00% 16.77B
-2.58%-3.93%-7.90%+493.42% 14.18B
+4.96%+4.63%-2.75%+864.40% 14B
Average +0.24%-3.34%+43.28%+237.33% 27.62B
Weighted average by Cap. +1.24%-1.99%+35.13%+170.03%

Financials

2026 *2027 *
Net sales 5.99M 5.19M 4.9M 4.44M 8.33M 574M 8.39M 58.49M 22.54M 291M 22.49M 22M 926M 293M 254M 240M 217M 408M 28.08B 411M 2.86B 1.1B 14.24B 1.1B 1.08B 45.28B
Net income -399M -346M -326M -296M -555M -38.24B -559M -3.9B -1.5B -19.4B -1.5B -1.47B -61.67B -202M -175M -165M -150M -281M -19.38B -283M -1.98B -761M -9.83B -760M -743M -31.26B
Net Debt -130M -112M -106M -96.18M -180M -12.43B -182M -1.27B -488M -6.3B -487M -476M -20.04B -206M -179M -169M -153M -287M -19.75B -289M -2.01B -776M -10.02B -774M -757M -31.86B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
14/09/26 $33.41 0.00% 1,437,396
11/09/26 $33.41 -1.97% 1,715,802
10/09/26 $34.08 -0.29% 2,264,643
09/09/26 $34.18 -3.12% 1,587,526
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
33.41USD
Average target price
55.82USD
Spread / Average Target
+67.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!